Abstract

Background

Confirming the efficacy of dolutegravir/lamivudine in clinical practice solidifies recommendations on its use.

Methods

Prospective cohort study (DUALING) in 24 human immunodeficiency virus (HIV) treatment centers in the Netherlands. HIV RNA–suppressed cases were on triple-drug antiretroviral regimens without prior virological failure or resistance and started dolutegravir/lamivudine. Cases were 1:2 matched to controls on triple-drug antiretroviral regimens by the use of dolutegravir-based regimens, age, sex, transmission route, CD4+ T-cell nadir, and HIV RNA zenith. The primary endpoint was the treatment failure rate in cases versus controls at 1 year by intention-to-treat and on-treatment analyses with 5% noninferiority margin.

Results

The 2040 participants were 680 cases and 1380 controls. Treatment failure in the 390 dolutegravir-based cases versus controls occurred in 8.72% and 12.50% (difference: −3.78% [95% confidence interval {CI}, −7.49% to .08%]) by intention-to-treat and 1.39% and 0.80% (difference: 0.59% [95% CI, –.80% to 1.98%]) by on-treatment analyses. The treatment failure risk in 290 non-dolutegravir-based cases was also noninferior to controls. Antiretroviral regimen modifications unrelated to virological failure explained the higher treatment failure rate by intention-to-treat. A shorter time on triple-drug antiretroviral therapy and being of non-Western origin was associated with treatment failure. Treatment failure, defined as 2 consecutive HIV RNA >50 copies/mL, occurred in 4 cases and 5 controls but without genotypic resistance detected. Viral blips occured comparable in cases and controls but cases gained more weight, especially when tenofovir-based regimens were discontinued.

Conclusions

In routine care, dolutegravir/lamivudine was noninferior to continuing triple-drug antiretroviral regimens after 1 year, supporting the use of dolutegravir/lamivudine in clinical practice.

Clinical Trials Registration

NCT04707326.

Details

Title
Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study
Author
Vasylyev, Marta 1 ; Ferdinand W N M Wit 2 ; Jordans, Carlijn C E 1 ; Soetekouw, Robin 3 ; Steven F L van Lelyveld 3 ; Gert-Jan Kootstra 4 ; Delsing, Corine E 4 ; Ammerlaan, Heidi S M 5 ; Marjo E E van Kasteren 6 ; Brouwer, Annemarie E 6 ; Leyten, Eliane M S 7 ; Claassen, Mark A A 8 ; Robert-Jan Hassing 8 ; den Hollander, Jan G 9 ; van den Berge, Marcel 10 ; Roukens, Anna H E 11 ; Bierman, Wouter F W 12 ; Groeneveld, Paul H P 13 ; Lowe, Selwyn H 14 ; van Welzen, Berend J 15 ; Richel, Olivier 16 ; Nellen, Jeannine F 17 ; Guido E L van den Berk 18 ; van der Valk, Marc 2 ; Rijnders, Bart J A 1 ; Casper Rokx 1 

 Section of Infectious Diseases, Department of Internal Medicine, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center , Rotterdam , The Netherlands 
 Stichting HIV Monitoring , Amsterdam , The Netherlands 
 Department of Internal Medicine, Spaarne Gasthuis , Haarlem/Hoofddorp , The Netherlands 
 Department of Internal Medicine, Medisch Spectrum Twente , Enschede , The Netherlands 
 Department of Internal Medicine, Catharina Ziekenhuis Eindhoven , Eindhoven , The Netherlands 
 Department of Internal Medicine, Elisabeth Tweesteden Ziekenhuis , Tilburg , The Netherlands 
 Department of Internal Medicine, Haaglanden Medisch Centrum , The Hague , The Netherlands 
 Department of Internal Medicine, Rijnstate Ziekenhuis , Arnhem , The Netherlands 
 Department of Internal Medicine, Maasstadziekenhuis , Rotterdam , The Netherlands 
10  Department of Internal Medicine, Admiraal de Ruyter Ziekenhuis , Vlissingen , The Netherlands 
11  Department of Infectious Diseases, Leiden University Medical Center , Leiden , The Netherlands 
12  Section of Infectious Diseases, Department of Internal Medicine, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands 
13  Department of Internal Medicine, Isala , Zwolle , The Netherlands 
14  Infectious Diseases and Infection Prevention, Department of Internal Medicine and Department of Medical Microbiology, Maastricht University Medical Center , Maastricht , The Netherlands 
15  Department of Internal Medicine, University Medical Center Utrecht , Utrecht , The Netherlands 
16  Section of Infectious Diseases, Department of Internal Medicine, Radboud University Medical Center , Nijmegen , The Netherlands 
17  Amsterdam Infection and Immunity Institute, Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam , The Netherlands 
18  Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis , Amsterdam , The Netherlands 
Publication year
2024
Publication date
Apr 2024
Publisher
Oxford University Press
e-ISSN
23288957
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3170970739
Copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.